COMPANY PROFILE

Neurotrope Bioscience

Neurotrope Bioscience engages in the development of diagnostic and therapeutic technologies for the treatment of neurodegenerative diseases

New York City, United StatesFounded 2012Biotech & Life Sciences

Valuation $100–250M Last recorded · 2013

Headcount <100 Current team size

Total funding $10–50M Disclosed equity funding

Unlock exact values

About Neurotrope Bioscience

Neurotrope is a clinical-stage biotech company focused on discovering and developing restorative therapeutics for patients suffering from neurodegenerative diseases and developmental disorders. The company leverages Bryostatin 1, a small molecule that penetrates the blood-brain barrier and activates protein kinase C, leading to improved synaptic function, new synapse formation, repair of damaged synapses, and prevention of neuronal death. Neurotrope's pipeline includes various treatment approaches for serious and difficult-to-treat diseases such as Alzheimer's Disease, Fragile X Syndrome, and Niemann-Pick Type C. The company operates in the biopharmaceutical market, targeting healthcare providers, research institutions, and pharmaceutical companies. Neurotrope generates revenue through partnerships, licensing agreements, and potential future product sales. The experienced team at Neurotrope has a deep expertise in neurodegenerative disorders and a successful track record in drug discovery and development.

MoreLess Source: Dealroom company data

At a glance

Status: Operational
Founded: 2012
Headquarters: New York City, United States
Employees: 4
Open positions: None listed
Dealroom signal: 24.7/100
Industry: Health
Sub-industry: BioTechnology
Sector: Biotech & Life Sciences, Biotechnology, Biotech and Pharma, Hard Tech, proteomics, DT and LS, science-based
Business model: Manufacturing
Links: Website LinkedIn

Knowledge graph

Founder mafia, market maps, research and news connected to this company by Dealroom

Funding history

1 recorded event

Company financing events and reported valuations.

Deal type	Date	Amount	Valuation	Investors	Source
SERIES A✓Equity / VC	Sep 2013	$22M	$88M	Undisclosed	—

Showing the latest 1 of 1 recorded eventsBook a demo for the full funding history →

Growth signals

Neurotrope Bioscience website traffic

Latest recorded traffic for Neurotrope Bioscience is 0 monthly website visits. Neurotrope Bioscience's team grew 0% over the past year.

Latest monthly visits0 1-year team growth0%

Monthly website visitsApr 2016–May 2020

Explore monthly traffic historyTrack growth over time and compare with peersBook a demo

Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Company	Headquarters	Status	Employees	Total funding	Valuation
NTNexo TherapeuticsUses a combination of covalent ligand discovery and chemical biology to develop new cancer therapies	Golden, United States	Operational	19	$60M	$240M
JLJunhe LeagueRecombinant protein drug developer	Hangzhou, China	Operational
CECellshootSearching for drug discovery target molecules and create groundbreaking new drug candidates	Tokyo, Japan	Operational
RARaeSedoGenerates and optimizes new, and improved structural peptidomimetics derived from active regions of SP-A	Arizona City, United States	Operational
BTBiolexis TherapeuticsReimagines drug discovery with it's proprietary FIELDS Technology	Sandy, United States	Operational
ETEngimmune TherapeuticsPlatform and product development company engineering next-generation T cell receptor therapies	Allschwil, Switzerland	Operational
CTCongruence TherapeuticsBuilding the leading pharmacological stabilizer company for the treatment of rare diseases	Montreal, Canada	Operational
PBProtai BioIlluminating the druggable Proteome for better cures	Tel Aviv-Yafo, Israel	Operational